The company is hoping that its accelerated R&D strategy and new launches will help offset the impact of upcoming patent ...

Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because ...

GSK's full-year 2025 results are due on 4. Learn what investors should watch including vaccines, specialty medicines and R&D investment levels.​ ...

GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.

Jan 20 (Reuters) - Britain's GSK will buy RAPT Therapeutics for $2.2 billion, adding global rights to the U.S. firm's experimental food allergy drug ozureprubart to its respiratory and immunology ...

GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...

GSK will buy RAPT Therapeutics for $2.2 billion, ‍the British drugmaker said on Tuesday, expanding its respiratory, ...

Bristol Myers Squibb BMY and GSK PLC GSK are among the largest global biopharma companies with broad and diverse portfolios.

GSK and CureVac forged their relationship during the Covid-19 pandemic, setting out to develop messenger RNA vaccines that could protect against the novel coronavirus and other infectious diseases.

GSK is staking billions on a new way to protect people from life‑threatening food allergies, agreeing to buy RAPT Therapeutics in a deal that values the California biotech at more than two billion ...

GSK acquires Rapt Therapeutics for $2.2B. Stock surges 65% as pharma giant gains access to phase 2b food allergy treatment ozureprubart.

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today a collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK) to ...